Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp120 vaccines prepared from SF-2 or MN strains of HIV-1. A total of 126 children were not infected; 21 received adjuvant only. Vaccine recipients developed lymphoproliferative responses on >/=2 occasions, responding more often to homologous HIV-1 antigens than did adjuvant recipients (56% vs. 14%; P<.001). Responses were appreciated after 2 immunizations and were maintained for >84 weeks after the last immunization. An accelerated immunization schedule (birth, 2 weeks, 2 months, and 5 months) with the lowest dose of the SF-2 vaccine produced responses in all 11 vaccinees by 4 weeks. Responses to heterologous envelope antigens were also detected. Immune responses to vaccination are achievable at an age when some infection (perinatal or breast milk exposure related) may be prevented.
Borkowsky
W
W
The Saul Krugman Division of Infectious Diseases and Immunology, New York University Medical School, New York, NY 10016, USA. borkow01@mcgc16.med.nyu.edu
Wara
D
D
Fenton
T
T
McNamara
J
J
Kang
M
M
Mofenson
L
L
McFarland
E
E
Cunningham
C
C
Duliege
A M
AM
Francis
D
D
Bryson
Y
Y
Burchett
S
S
Spector
S A
SA
Frenkel
L M
LM
Starr
S
S
Van Dyke
R
R
Jimenez
E
E
D016915:AIDS Vaccines / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007223:Infant; D007231:Infant, Newborn; D008213:Lymphocyte Activation; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic